You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Under the plan, the president will establish a national pandemic testing board to oversee implementation of a unified approach to testing.
While some remain concerned that the bill will reduce labs' leverage with payors, provisions like the use of arbitration for disputes are a win for providers.
Some insiders emphasize the importance of doing rapid turnaround testing of asymptomatic people, while others contend lab tests ought to be the modality of choice.
The COVID-19 pandemic is the highest priority for most, but laboratory organizations are also looking ahead with longer-term goals for the new presidency.
Reimbursement and liability issues will be impacted by FDA's decision, while LDT users could find it difficult to assess the quality of the new tests.
If the lateral flow assay receives US regulatory approval, it would be the first antigen test for use in both symptomatic and asymptomatic individuals.
Federal mandates requiring frequent SARS-CoV-2 testing for nursing home employees and significant purchases of rapid antigen tests from HHS have raised concerns about capacity.
Some lab experts say that Abbott's test is open to multiple variables, which could lead to improper use and incorrect test results.
The letter cited the strain on non-COVID-19 care as laboratories struggle to meet demand for pre-procedure COVID-19 testing and other molecular tests.